Skip to main content
Journal of Pharmacy & Bioallied Sciences logoLink to Journal of Pharmacy & Bioallied Sciences
. 2025 Apr 21;17(Suppl 1):S92–S95. doi: 10.4103/jpbs.jpbs_1493_24

Navigating the Vaginal Milieu During Perimenopause: A Narrative Review of Physiological Changes and Clinical Implications

Megha Tiwari 1,, Neema Acharya 2, Manjusha Mahakarkar 1
PMCID: PMC12156567  PMID: 40511019

ABSTRACT

Perimenopause represents a transitional phase in a woman’s life, marked by significant hormonal and physiological changes that profoundly impact the vaginal milieu. These changes can lead to a variety of symptoms, collectively known as genitourinary syndrome of menopause, affecting a woman’s sexual health, quality of life, and overall well-being. This narrative review aims to explore the underlying physiological alterations in the vaginal environment during perimenopause, their clinical implications, and current therapeutic approaches. By highlighting the challenges and emerging strategies in managing these changes, this review provides insights into personalized treatment options for improving women’s health during this crucial period.

KEYWORDS: Genitourinary syndrome of menopause (GSM), hormonal changes, perimenopause, therapeutic strategies, vaginal microbiome, vaginal milieu

INTRODUCTION

Perimenopause, often referred to as the menopausal transition, is a phase characterized by hormonal fluctuations that precede menopause. Typically occurring in women between the ages of 40 and 50, this period is marked by irregular menstrual cycles, vasomotor symptoms, and profound changes in the reproductive and urogenital systems. One of the most affected areas during this transition is the vaginal milieu, where hormonal alterations lead to noticeable physical and functional changes.[1]

Understanding the changes in the vaginal environment during perimenopause is crucial for addressing symptoms that can significantly impair quality of life. The decline in estrogen levels affects the structure and function of the vaginal tissue, leading to a condition known as genitourinary syndrome of menopause (GSM). This review delves into the physiological mechanisms driving these changes, their clinical manifestations, and potential therapeutic strategies that can help alleviate symptoms and improve patient outcomes.[2]

PHYSIOLOGICAL CHANGES IN THE VAGINAL MILIEU DURING PERIMENOPAUSE

Hormonal changes

The perimenopausal phase is predominantly driven by a decline in estrogen and progesterone levels, which play a critical role in maintaining the integrity of the vaginal tissue. Estrogen supports the thickness, elasticity, and lubrication of the vaginal mucosa. Its reduction during perimenopause leads to thinning of the epithelial layer, decreased blood flow, and reduced glandular secretions. These hormonal shifts contribute to increased vaginal dryness, reduced elasticity, and a more fragile tissue structure.[3]

Changes in vaginal epithelium

The vaginal epithelium undergoes significant atrophy during perimenopause due to declining estrogen levels. This thinning of the vaginal walls is accompanied by a decrease in the epithelial cell turnover rate, making the tissue more susceptible to mechanical irritation and microtrauma. Reduced glycogen production also occurs, which has a downstream effect on the vaginal microbiome.[3]

Vaginal pH and microbiome alterations

Under normal, premenopausal conditions, the vaginal pH is maintained at a slightly acidic level (typically between 3.5 and 4.5) due to the presence of lactobacilli that produce lactic acid. During perimenopause, the decrease in estrogen results in reduced glycogen content in the epithelial cells, leading to a decrease in lactobacilli populations. Consequently, the vaginal pH becomes more alkaline, creating a less favorable environment for beneficial bacteria and increasing the risk of colonization by pathogenic organisms.[4]

Lubrication and vascularity

The natural lubrication of the vagina is closely linked to estrogen-driven vascularization. As estrogen levels decline, there is a notable reduction in blood flow to the vaginal tissues, leading to decreased lubrication. This diminished lubrication contributes to vaginal dryness and discomfort during sexual activity, known as dyspareunia. The lack of adequate moisture can also cause itching, burning, and increased sensitivity in the vaginal area.[5]

Implications on sexual function and comfort

Sexual dysfunction is a common concern among perimenopausal women due to changes in the vaginal milieu. The combination of dryness, reduced elasticity, and discomfort can lead to a decrease in sexual desire, arousal difficulties, and painful intercourse. These factors not only affect physical intimacy but can also have a significant impact on a woman’s emotional and psychological well-being.[5]

CLINICAL IMPLICATIONS OF VAGINAL CHANGES DURING PERIMENOPAUSE

Genitourinary syndrome of menopause

GSM is a comprehensive term encompassing the various symptoms resulting from estrogen deficiency, including vaginal dryness, irritation, and urinary symptoms. Women may experience increased frequency, urgency, and recurrent urinary tract infections (UTIs), which significantly affect their quality of life.[6]

Sexual dysfunction

Sexual dysfunction during perimenopause is not solely a physical issue; it often involves psychological and emotional aspects. The pain and discomfort caused by vaginal dryness can lead to avoidance of sexual activity, reduced libido, and strained intimate relationships. Addressing these issues requires a holistic approach that considers both the physical and emotional dimensions of sexual health.[7]

Increased susceptibility to infections

Changes in the vaginal pH and microbiome during perimenopause create a conducive environment for pathogenic bacteria to thrive. Women are at a higher risk of developing bacterial vaginosis, yeast infections, and UTIs due to the reduced presence of lactobacilli. Proper diagnosis and timely treatment are crucial to prevent complications and ensure vaginal health.[8]

Impact on quality of life

The cumulative effects of vaginal discomfort, sexual dysfunction, and recurrent infections can lead to a significant decline in a woman’s overall well-being. Social interactions, self-esteem, and daily activities may be affected, highlighting the need for comprehensive care that addresses both physical and psychological aspects of health.[9]

DIAGNOSTIC APPROACHES

Clinical assessment

A thorough patient history and physical examination are fundamental in diagnosing vaginal changes during perimenopause. Clinicians should inquire about symptoms such as vaginal dryness, itching, pain during intercourse, and urinary complaints to develop a comprehensive treatment plan.[10]

Laboratory tests and vaginal assessment

Laboratory evaluations, including measuring vaginal pH, hormone levels, and microbiome analysis, can provide valuable insights into the underlying physiological changes. High vaginal pH levels and decreased lactobacilli concentrations are indicative of altered vaginal health.[11]

Imaging techniques

Ultrasound and other imaging techniques can help assess structural changes in the pelvic region, identify abnormalities, and guide treatment plans, especially in cases where other underlying gynecological issues are suspected.[12]

MANAGEMENT AND THERAPEUTIC STRATEGIES

Non-pharmacological interventions

Nonpharmacological strategies play a vital role in managing vaginal changes during perimenopause:

  • Lifestyle Modifications: Maintaining a healthy diet, regular exercise, and adequate hydration can help alleviate some symptoms.[13]

  • Pelvic Floor Exercises: Strengthening pelvic floor muscles through exercises like Kegels can improve blood flow and support vaginal tone.[13]

Pharmacological therapies

  • Hormone Replacement Therapy (HRT): Systemic and local estrogen therapies are effective in restoring vaginal health by thickening the epithelium and enhancing lubrication. However, HRT should be personalized based on the patient’s medical history and risk factors.[14]

  • Local Estrogen Therapy: Topical estrogen products, such as creams, tablets, and vaginal rings, directly target vaginal tissues, reducing systemic side effects and effectively managing GSM symptoms.[14]

  • Nonhormonal Options: Moisturizers and lubricants provide symptomatic relief from vaginal dryness. Selective estrogen receptor modulators like ospemifene offer nonhormonal alternatives for managing GSM.[14]

Emerging therapies

  • Laser and Radiofrequency Treatments: Minimally invasive therapies like CO2 laser and radiofrequency have shown promising results in rejuvenating vaginal tissue, enhancing collagen production, and improving elasticity.[15]

  • Probiotics: Oral and vaginal probiotics may help restore the balance of beneficial bacteria, reducing the risk of infections and maintaining a healthy vaginal microbiome.[15]

  • Phytoestrogens: Plant-based compounds found in soy, flaxseed, and red clover may act as natural alternatives to estrogen, offering relief from mild GSM symptoms.[15]

Psychological and psychosocial aspects

The impact of vaginal changes extends beyond the physical realm, influencing mental health and quality of life. Feelings of inadequacy, anxiety, and depression are common among women dealing with sexual dysfunction and discomfort. Healthcare providers play a crucial role in offering psychological support, encouraging open communication, and addressing the emotional aspects of these changes.[16]

Future directions and research gaps

Despite advancements in understanding the vaginal milieu during perimenopause, significant research gaps remain. More longitudinal studies are needed to evaluate the long-term effects of emerging therapies, understand the role of the vaginal microbiome, and develop personalized treatment strategies. Exploring innovative approaches in regenerative medicine could pave the way for new therapeutic avenues.[2]

CONCLUSION

Perimenopause is a complex transition marked by profound physiological changes in the vaginal milieu that significantly affect women’s health and well-being. Recognizing the clinical implications and adopting a personalized approach to management can help alleviate symptoms and improve the quality of life for perimenopausal women. Continued research and the development of innovative therapies will be essential in addressing the multifaceted challenges of this transitional phase.

Conflicts of interest

There are no conflicts of interest.

Funding Statement

Nil.

REFERENCES

  • 1.Talaulikar V. Menopause transition: Physiology and symptoms. Best Pract Res Clin Obstet Gynaecol. 2022;81:3–7. doi: 10.1016/j.bpobgyn.2022.03.003. [DOI] [PubMed] [Google Scholar]
  • 2.Santoro N. Perimenopause: From research to practice. J Womens Health (Larchmt) 2016;25:332–9. doi: 10.1089/jwh.2015.5556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Delamater L, Santoro N. Management of the perimenopause. Clin Obstet Gynecol. 2018;61:419–32. doi: 10.1097/GRF.0000000000000389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Navarro S, Abla H, Delgado B, Colmer-Hamood JA, Ventolini G, Hamood AN. Glycogen availability and pH variation in a medium simulating vaginal fluid influence the growth of vaginal Lactobacillus species and Gardnerella vaginalis. BMC Microbiol. 2023;23:186. doi: 10.1186/s12866-023-02916-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Nappi RE, Martini E, Cucinella L, Martella S, Tiranini L, Inzoli A, et al. Addressing vulvovaginal atrophy (VVA)/Genitourinary syndrome of menopause (GSM) for healthy aging in women. Front Endocrinol (Lausanne) 2019;10:561. doi: 10.3389/fendo.2019.00561. doi: 10.3389/fendo.2019.00561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kim HK, Kang SY, Chung YJ, Kim JH, Kim MR. The recent review of the genitourinary syndrome of menopause. J Menopausal Med. 2015;21:65–71. doi: 10.6118/jmm.2015.21.2.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Thornton K, Chervenak J, Neal-Perry G. Menopause and sexuality. Endocrinol Metab Clin North Am. 2015;44:649–61. doi: 10.1016/j.ecl.2015.05.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Park MG, Cho S, Oh MM. Menopausal changes in the microbiome—A review focused on the genitourinary microbiome. Diagnostics (Basel) 2023;13:1193. doi: 10.3390/diagnostics13061193. doi: 10.3390/diagnostics13061193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Moshfeghy Z, Tahari S, Janghorban R, Najib FS, Mani A, Sayadi M. Association of sexual function and psychological symptoms including depression, anxiety and stress in women with recurrent vulvovaginal candidiasis. J Turk Ger Gynecol Assoc. 2020;21:90–6. doi: 10.4274/jtgga.galenos.2019.2019.0077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Valadares ALR, Kulak Junior J, Paiva LHS da C, Nasser EJ, Silva CR da, Nahas EAP, et al. Genitourinary syndrome of menopause. Rev Bras Ginecol Obstet. 2022;44:319–24. doi: 10.1055/s-0042-1748463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, et al. The vaginal microbiome: New information about genital tract flora using molecular based techniques. BJOG. 2011;118:533–49. doi: 10.1111/j.1471-0528.2010.02840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Karena ZV, Mehta AD. Sonography Female Pelvic Pathology Assessment, Protocols, and Interpretation. StatPearls. StatPearls Publishing. 2023 [PubMed] [Google Scholar]
  • 13.Goldstein KM, McDuffie JR, Shepherd-Banigan M, Befus D, Coeytaux RR, Van Noord MG, et al. Nonpharmacologic, nonherbal management of menopause-associated vasomotor symptoms: An umbrella systematic review (protocol) Syst Rev. 2016;5:56. doi: 10.1186/s13643-016-0232-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lee SR, Cho MK, Cho YJ, Chun S, Hong SH, Hwang KR, et al. The 2020 menopausal hormone therapy guidelines. J Menopausal Med. 2020;26:69–98. doi: 10.6118/jmm.20000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Welk B, Kelly E. Laser devices for vaginal rejuvenation: Effectiveness, regulation and marketing. CMAJ. 2023;195:E195–6. doi: 10.1503/cmaj.221208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Malhi GS, Bell E. Questions in psychiatry (QuiP): Psychological basis for sexual dysfunction in psychiatry. Bipolar Disord. 2022;24(8):830–3. doi: 10.1111/bdi.13273. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Pharmacy & Bioallied Sciences are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES